Cardiotonic Agents Market Developments by 2031
MARKET ANALYSIS
Cardiotonic agents are medicines used to improve contractile power of myocardium which helps in the effective blood circulation. Cardiac insufficiency leads to insufficient blood supply to organs which causes weariness, breathlessness, and edema. Ischemic heart disease and arterial hypertension are the two main causes of cardiac insufficiency and the drugs used for its treatment known as cardiotonic agents. There are several other medications such as glycosides, sympathomimetics, and others used for the treatment of congestive heart failure, cardiac surgical procedures, shock, and other conditions.
GROWTH DRIVERS AND CHALLENGES
New and improved cardiotonic drugs are constantly being developed and launched in the global market. Several innovative medications are being created to focus on particular heart failure mechanisms. The effectiveness of available medications can be enhanced by the creation of new drugs with reduced side effects. The World Health Organisation (WHO) estimates that four out of every five deaths from cardiovascular disorders are attributable to cardiovascular diseases, such as heart attacks and strokes.
The market for cardiotonic agents expected to experience new growth prospects as personalized medical techniques such as genetic testing become more prevalent. Healthcare professionals are inclining towards personalize therapy for patients by locating specific genetic markers linked to heart failure, perhaps improving outcomes. Additionally, various factors such as an aging population, hypertension, myocardial infarction, and heart failure are anticipated to support the cardiotonic agents market growth. According to Heart Society of America, by 2031, more than 6.5 million North Americans is expected to have heart failure, bringing the total to more than 8 million. Furthermore, Heart Society of America also stated that, the overall cost of care for North Americans with heart failure is anticipated to increase from $30.7 billion in 2012 to 69.7 billion in 2031 due to the increasing number of patients.
REPORT SEGMENTATION AND SCOPE
The "Global Cardiotonic agents market Analysis to 2031" is a specialized and in-depth study focusing on the global cardiotonic agents market trends and growth opportunities. The report aims to provide an overview of the global cardiotonic agents market with detailed market segmentation by drug type, testing type, application, dosage form, route of administration, distribution channel, and geography. The global cardiotonic agents market has witnessed high growth over the recent past and is expected to continue this trend during the forecast period. The report provides key statistics on the uses of cardiotonic agents worldwide and their demand in major regions and countries. In addition, the report provides a qualitative assessment of various factors affecting the cardiotonic agents market performance in major regions and countries. The report also includes a comprehensive analysis of the leading cardiotonic agents market players and their key strategic developments. Several analyses on the market dynamics are also included to help identify the key driving factors, market trends, and lucrative cardiotonic agents market opportunities that would, in turn, aid in identifying the major revenue pockets.
Further, ecosystem analysis and Porter's five forces analysis provide a 360-degree view of the global cardiotonic agents market. This helps understand the entire supply chain and various market growth factors.
SEGMENTAL ANALYSIS
The global cardiotonic agents market size is segmented based on drug type, application, route of administration, dosage form, distribution channel, and geography. The cardiotonic agents market is segmented based on drug type as digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. The increasing use of phosphodiesterase inhibitors is anticipated to increase the market for cardiotonic agents. Based on application, the market is classified as cardiac surgical procedures, atrial fibrillation, heart failure, pulmonary hypertension, and others.. Cardiac surgical procedure held the largest market share in 2022 and is anticipated to expand steadily during the forecast period owing to increased demand for cardiac surgeries such as valve replacement, bypass surgeries, and heart transplants.
Furthermore, the route of administration is bifurcated into oral and parenteral. Based on dosage form, the market is classified into tablets, solutions, and others. Based on the distribution channel cardiotonic agents market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
REGIONAL FRAMEWORK
REGIONAL ANALYSIS
The North America cardiotonic agent market is expected to dominate the global market owing to high prevalence of cardiovascular diseases, increased healthcare spending, and advanced healthcare infrastructure. The US holds the largest market share in North America cardiotonic agents market because the majority of key players such Novartis, Merck & Co., Amgen, Pfizer, and others are operating in the US. These companies are actively involved in the product development, innovation, and marketing of cardiotonic drugs. For instance, In January 2022, Merck & Co., Inc. announced the phase II clinical trial completion of Vericiguat, which improves cardiac function by activating guanylate cyclase.
Furthermore, Asia Pacific anticipated the highest CAGR in global cardiotonic agents market, owing to the rising prevalence of cardiovascular disorders among geriatric population. Cardiotonic agents' market expansion has been significantly influenced by the medical community owing to the significant increase in awareness of the potential benefits of these drugs. In addition, increasing disposable incomes and a growing prevalence of cardiovascular diseases are likely to create demand for these drugs in Asia Pacific.
INDUSTRY DEVELOPMENTS AND FUTURE OPPORTUNITIES
Partnerships, acquisitions, product approvals, product developments, and new product launches were found to be the major strategies adopted by the players operating in the global cardiotonic agents market.
- In February 2022, Roche completed the phase III clinical trials for its furosemide drug. This drug is used in heart failure conditions; it's a loop diuretic that lowers fluid build-up in the body and improves cardiac function.
- In November 2021, Novartis completed the phase III clinical trials for its oral thrombin inhibitor drug, Entresto. This drug is used in heart failure conditions, with preserved ejection fraction. It's a major form of heart failure and is difficult to treat.
- In December 2019, Pfizer Inc. completed the phase III clinical trials for its oral thrombin inhibitor, betrixaben drug. Betrixaben is used to prevent blood clots in acutely ill medical patients.
IMPACT OF COVID/IMPACT OF GEOPOLITICAL SCENARIO/IMPACT OF RECESSION
The covid-19 pandemic led to a decline in the progress of many industries across the globe. The closure of manufacturing plants and restricted trade across the globe led to supply chain constraints for manufacturers across the globe. The cardiotonic agents market growth experienced sudden decline during the pandemic due to the limited supply of drugs and the decrease in the number of cardiac surgeries globally. This is because of the cancellation of many non-essential surgical procedures across the world. Conversely, the cardiotonic agents market is growing after the significant efforts taken by market stakeholders and healthcare practitioners to manage the disrupted supply chain. The rising demand for cardiotonic agents owing to increasing incidences of heart failure and the rise in the geriatric population prone to cardiovascular conditions are driving the market growth. In 2021, the roll out of COVID-19 vaccines has created the positive outcomes which led to the increased production to fulfil the rising demand from large population. Additionally, the patient recovered from COVID-19 is experiencing the cardiovascular problems which are likely to intensify the demand for cardiotonic agents in the near future.
Cardiotonic Agents market Market Report Analysis
CAGR (2023 - 2031)
US$ XX Million
US$ XX Million
Report Coverage
Key Players
Regional Overview
Market Segmentation
By Drug Type
By Application
By Route of Administration
By Dosage Form
COMPETITIVE LANDSCAPE AND KEY COMPANIES
Some of the key players operating in the cardiotonic agents market include Amneal Pharmaceuticals LLC, Midas Pharma GmbH, Novartis, Pfizer Inc., Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi, Midas Pharma GmbH, Sanofi, Aurobindo Pharma Limited, and SimSon Pharma Limited among others
Cardiotonic Agents market Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Drug Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies
1. Amneal Pharmaceuticals LLC
2. Pfizer Inc.
3. Hikma Pharmaceuticals PLC
4. Fresenius Kabi
5. Midas Pharma GmbH
6. Sanofi
7. Aurobindo Pharma Limited
8. SimSon Pharma Limited.
9. Novartis
10. Merck & Co. Inc.
Get Free Sample For